Recombinant DNA or rDNA is a type of artificial DNA, which is developed by joining two or more DNA strands and the rDNA technology is a technology that allows DNA to be created artificially. This technology is used to alter DNAs in living organisms and is expected to have even more practical uses in future. Over the past couple of years, this tech has showcased major impacts in bringing improvements in human life and health. The best example would be Humulin, insulin for the treatment of diabetes, which is produced using rDNA tech.
How rDNA Technology is Improving Human Health
The rDNA technology has a number of applications and potential to tackle various essential aspects of life, for instance, improving health and enhancing food resources. Moreover, recombinant pharmaceuticals are now being adopted quickly and are rapidly attaining commercial approvals. The rDNA techniques use the latest methods and tools like molecular cloning, which yield more reliable products in lesser period. Thus, this technology is playing a major role in improving human health by supporting the development of innovative vaccines and pharmaceuticals.
Pharmaceutical and Biotech Firms: Major Beneficiaries of rDNA Tech
The advent of rDNA and various pharma products developed using this tech have completely changed and revolutionized the human life. rDNA technology offers new opportunities to create medically valuable and innovative therapeutic products with immediate effect in biomedicine and medical genetics by altering plants, animals, and microorganisms.
The rDNA technology has a wide range of end-use segments including pharmaceutical and biotechnology firms, academic and government research institutes, and others. Among these, pharma and biotech firms are the major users of rDNA tech as it boosts up the drug development capabilities of such firms. In addition, the products developed using rDNA techniques are highly valued and have considerable improvement in productivity. These firms are expected to be the key end-user segments even in the future on account of growing adoption of biologics production.
For example, the US FDA has approved Kymriah, the first US gene therapy for the treatment of leukemia by Novartis Corp. in partnership with University of Pennsylvania. Each dose of this new drug contains a patient’s own immune cells that have been modified genetically, thereby giving a second chance to the receiver.
Market Overview
Findings of a research report by Grand View Research, Inc. estimated that the worldwide rDNA technology market may reach at USD 84.6 billion by 2025. Successful application of rDNA technology in gene therapy and in the production of genetically modified veterinary products, bio-pesticides, and biofuel is said to augment market growth from 2017 to 2025. Key companies in the global market are Biogen, Inc.; F. Hoffmann-La Roche Ltd.; Monsanto Co.; Amgen Inc.; Eli Lilly and Co.
In-Depth Research Report On Recombinant DNA Technology Market:
https://www.grandviewresearch.com/industry-analysis/recombinant-dna-technology-market
No comments:
Post a Comment